Vectura Group PLC (LON:VEC) had its target price reduced by J P Morgan Chase & Co from GBX 180 ($2.37) to GBX 175 ($2.30) in a report issued on Friday morning. J P Morgan Chase & Co currently has an overweight rating on the stock.
Several other analysts also recently issued reports on VEC. Panmure Gordon reissued a buy rating and issued a GBX 150 ($1.97) price target on shares of Vectura Group PLC in a research note on Thursday, November 9th. Peel Hunt restated a hold rating and issued a GBX 160 ($2.10) price objective on shares of Vectura Group PLC in a report on Thursday, November 9th. Shore Capital restated a buy rating on shares of Vectura Group PLC in a report on Wednesday, August 16th. Numis Securities Ltd decreased their price objective on Vectura Group PLC from GBX 205 ($2.70) to GBX 170 ($2.24) and set a buy rating for the company in a report on Thursday, November 9th. Finally, Citigroup Inc. decreased their price objective on Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating for the company in a report on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of GBX 189.67 ($2.49).
Shares of Vectura Group PLC (VEC) opened at GBX 90.45 ($1.19) on Friday. Vectura Group PLC has a 12 month low of GBX 86.50 ($1.14) and a 12 month high of GBX 166.97 ($2.20).
In other Vectura Group PLC news, insider Bruno Angelici purchased 70,000 shares of Vectura Group PLC stock in a transaction that occurred on Tuesday, September 12th. The stock was acquired at an average price of GBX 99 ($1.30) per share, for a total transaction of £69,300 ($91,148.23). Also, insider Andrew Derodra purchased 82,000 shares of Vectura Group PLC stock in a transaction that occurred on Thursday, September 7th. The shares were acquired at an average price of GBX 90 ($1.18) per share, with a total value of £73,800 ($97,066.95). Insiders have purchased 152,456 shares of company stock valued at $14,354,880 in the last quarter.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.